Suggested remit - To appraise the clinical and cost-effectiveness of nivolumab with ipilimumab within its marketing authorisation for adjuvant treatment of completely resected stage III or IV melanoma
Following on from information provided to NICE by the company in December 2020, the appraisal of Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma [ID1610] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1610
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 21 November 2022 | Note added to the project documents |
| 21 November 2022 | Discontinued. Following on from information provided to NICE by the company in December 2020, the appraisal of Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma [ID1610] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 10 December 2020 | Note added to the project documents |
| 10 December 2020 | Suspended. Topic is suspended |
| 13 September 2019 - 11 October 2019 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 09 August 2019 | In progress. Referred 31 July 2017 |
For further information on our processes and methods, please see our CHTE processes and methods manual